Sanofi SA
PAR:SAN
Sanofi SA
Gross Profit
Sanofi SA
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sanofi SA
PAR:SAN
|
Gross Profit
€64.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ipsen SA
PAR:IPN
|
Gross Profit
€3B
|
CAGR 3-Years
9%
|
CAGR 5-Years
6%
|
CAGR 10-Years
11%
|
|
|
Vetoquinol SA
PAR:VETO
|
Gross Profit
€262.3m
|
CAGR 3-Years
1%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
Virbac SA
PAR:VIRP
|
Gross Profit
€937.6m
|
CAGR 3-Years
23%
|
CAGR 5-Years
15%
|
CAGR 10-Years
10%
|
|
|
Boiron SA
PAR:BOI
|
Gross Profit
€350.9m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-3%
|
|
|
Medincell SA
PAR:MEDCL
|
Gross Profit
€9.8m
|
CAGR 3-Years
11%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
Sanofi SA
Glance View
Sanofi SA, a titan in the global healthcare sector, operates at the intricate crossroads of pharmaceutical innovation and patient care, driven by an unyielding commitment to improving human health. Emerging from its French roots, Sanofi has strategically positioned itself as a global leader in pharmaceuticals, vaccines, and consumer healthcare. The company’s success is essentially anchored in its capacity to consistently develop and commercialize life-saving drugs that address a myriad of health concerns, ranging from diabetes and cardiovascular diseases to rare disorders and oncology. Underlining its robust revenue engine is Sanofi's extensive R&D infrastructure that fuels its pipeline with groundbreaking therapies, reflecting a dynamic blend of scientific acumen and market-focused agility. By leveraging a hybrid model that integrates cutting-edge research with strategic alliances and acquisitions, Sanofi ensures a sustained presence in the highly competitive biopharmaceutical landscape. Enabling this network of innovation and impact is Sanofi's diverse portfolio, a balanced mix of specialty and established prescription drugs, over-the-counter products, and the critical arm of vaccines led by its Sanofi Pasteur division. This diversification offers both growth opportunities and stability, cushioning against the volatile tides of patent expirations and regulatory changes. Its vaccines segment, in particular, is a cornerstone in Sanofi's business, capturing substantial market share with products critical to global immunization efforts, further amplified by its role in responding to health emergencies like the COVID-19 pandemic. With a geographically expansive sales footprint and strategic marketing strategies, Sanofi capitalizes on emerging market opportunities while maintaining a strong presence in established regions, effectively making its bottom line a testimony to its operational excellence and strategic foresight in harmonizing science with humanity.
See Also
What is Sanofi SA's Gross Profit?
Gross Profit
64.5B
EUR
Based on the financial report for Mar 31, 2025, Sanofi SA's Gross Profit amounts to 64.5B EUR.
You don't have any saved screeners yet